INO Stock News: Inovio Pharmaceuticals Inc has room to rise amid two covid vaccine advantages

  • NASDAQ: INO is set to end the week with a steady upside gain.
  • Inovio Pharmaceuticals Inc is still in the COVID-19 vaccine race amid two major advantages. 
  • The pharma firm has other products in its pipeline which make it a potentially profitable long-term investment. 

With Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) try to beat each other with efficacy levels of their COVID-19 vaccines, it may be easy to forget about other efforts such as that of Inovio Pharmaceuticals Inc (NASDAQ: INO). The Plymouth Meeting, Pennsylvania-based pharma firm is also in the race to develop coronavirus immunization – a contest that may have more than one or two winners. 

Inovio has received permission to begin a Phase 2/3 trial called Innovate on November 16. While the firm's INO-4800's vaccine candidate needs two doses – like the others – it has other advantages. 

First, the inoculation can be stored at room temperature for a full year, easing its distribution and storage. Costs are also likely to be lower. Another factor in its favor – yet currently questioned by the regulator – is the ability to deliver the dose directly through the skin. Inovio's Cellectra 2000 device is needed for administering the vaccine, yet it is simpler than an outright injection. 

Inovio's Phase 1 trial has shown that the immunization candidate prompts the creation of both antibodies and T-cells. Even if the first vaccines that Americans and others receive do not come from Inovio, the easy storage and application of this protection could be used as a seasonal boost later on

Moreover, the company uses its DNA approach to develop other drugs. These include cancer, infectious disease, and human papillomavirus. That makes NASDAQ: INO a potential long-term investment. 

Inovio Pharmaceuticals Stock

NASDAQ: INO is quoted at $11.20 in Friday's pre-market trading. Shares are up some 1.63% after dropping by 0.1% on Thursday. Calm trading is relatively new to Inovio's shares, which have ranged between the $8 handle the $12 one during November. 

The firm is valued at $1.87 billion, making it a small company in comparison to other pharmaceutical firms. There is substantial room to go toward the 52-week high of $33.79. 


Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

Latest Forex News

Latest Forex News

Editors’ Picks

EUR/USD hits fresh two-month highs amid dollar weakness

EUR/USD has hit new two-month highs above 1.1940 as the dollar resumes its decline. Optimism about the US transition and covid vaccines is weighing on the safe-haven dollar. 


GBP/USD falls toward 1.33 amid Brexit acrimony

GBP/USD is falling toward 1.33 as both the EU and the UK are busy blaming each other for an impasse in Brexit talks. The thorny issues remain fisheries, governance and setting a level playing field.


XAU/USD attempting to bounce up from $1,775 low

Gold futures accelerated heir downtrend from last week highs near $1,900, breaking below the 200-day SMA, at $1,800 area, to hit its lowest prices in nearly five months, at $1,775.

Gold news

Dollar offered ahead of the weekend

Equities are finishing the week on a firm tone, while the US dollar remains heavy. In the Asia Pacific, only Australia and India did not end the week on a firm note.

Read more

Black Friday 2020 Discounts!

Learn to trade with the best! Don't miss the most experienced traders and speakers in FXStreet Premium webinars. Also if you are a Premium member you can get real-time FXS Signals and receive daily market analysis with the best forex insights!

More info